Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
17.29
-1.13 (-6.13%)
Sep 26, 2024, 4:00 PM EDT - Market closed
Zenas BioPharma Revenue
Zenas BioPharma had revenue of $50.00M in the twelve months ending June 30, 2024. In the year 2023, Zenas BioPharma had annual revenue of $50.00M.
Revenue (ttm)
$50.00M
Revenue Growth
n/a
P/S Ratio
4.65
Revenue / Employee
$438,596
Employees
114
Market Cap
688.01M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 50.00M | - | - |
Dec 31, 2022 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionZBIO News
- 7 days ago - Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering - GlobeNewsWire
- 12 days ago - U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market - Seeking Alpha
- 14 days ago - Zenas BioPharma Announces Pricing of Upsized Initial Public Offering - GlobeNewsWire
- 19 days ago - U.S. IPO Weekly Recap: 2 APAC Microcaps Go Public In Short Labor Day Week As The Pipeline Grows - Seeking Alpha
- 4 weeks ago - Zenas BioPharma Seeks IPO For Inflammatory Treatment Trials - Seeking Alpha
- 4 weeks ago - U.S. IPO Weekly Recap: WeRide Delays Its IPO As Pipeline Gets A Boost - Seeking Alpha
- 5 weeks ago - Immunology-focused biotech Zenas BioPharma files for an estimated $150 million IPO - Renaissance Capital
- 5 weeks ago - Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO - Reuters